Can *APC* mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families

W Friedl, R Caspari, M Sengteller, S Uhlhaas, C Lamberti, M Jungck, M Kadmon, M Wolf, J Fahnenstich, J Gebert, G Möslin, E Mangold, P Propping

Abstract

Background and aims—In familial adenomatous polyposis (FAP), correlations between site of mutation in the adenomatous polyposis coli (*APC*) gene and severity of colonic polyposis or extracolonic manifestations are well known. While mutation analysis is important for predictive diagnosis in persons at risk, its relevance for clinical management of individual patients is open to question.

Methods—We examined 680 unrelated FAP families for germline mutations in the *APC* gene. Clinical information was obtained from 1256 patients.

Results—*APC* mutations were detected in 48% (327/680) of families. Age at diagnosis of FAP based on bowel symptoms and age at diagnosis of colorectal cancer in untreated patients were used as indicators of the severity of the natural course of the disease. A germline mutation was detected in 230 of 404 patients who were diagnosed after onset of bowel symptoms (rectal bleeding, abdominal pain, diarrhoea). When these patients were grouped according to the different sites of mutations, mean values for age at onset of disease differed significantly: patients carrying *APC* mutations at codon 1309 showed a disease onset 10 years earlier (mean age 20 years) compared with patients with mutations between codons 168 and 1580 (except codon 1309) (mean age 30 years), whereas patients with mutations at the 5' end of codon 168 or the 3' end of codon 1580 were diagnosed at a mean age of 52 years. Within each group of patients however large phenotypic variation was observed, even among patients with identical germline mutations. A higher incidence of desmoids was found in patients with mutations between codons 1445 and 1580 compared with mutations at other sites, while no correlation between site of mutation and presence of duodenal adenomas was observed.

Conclusions—As age at manifestation and course of the disease may be rather variable, even in carriers of identical germline mutations, therapeutic decisions should be based on colonoscopic findings in individual patients rather than on the site of mutation. However, in patients with mutations within codons 1445–1580, it may be advisable to postpone elective colectomy because desmoids may arise through surgical intervention.

(Gut 2001;48:515–521)

Keywords: familial adenomatous polyposis; *APC* gene; genotype-phenotype correlation; phenotypic variation

Familial adenomatous polyposis (FAP) is an autosomal dominant precancerous condition of the colorectum. In typical FAP, patients develop hundreds to thousands of adenomatous polyps. Colorectal symptoms such as rectal bleeding, diarrhoea, and abdominal pain occur in untreated patients at an average age of 29 years, and patients die from colorectal cancer (CRC) at an average age of 40 years.^{1 2} FAP is caused by germline mutations in the adenomatous polyposis coli (*APC*) gene which encodes a tumour suppressor protein consisting of 2843 amino acids.^{3 4} The *APC* protein is involved in downregulation of free intracellular β -catenin, a central component of the E-cadherin adhesion complex and the *wnt* signalling pathway.⁵

The majority of germline mutations identified in FAP patients are distributed over the 5' half of the *APC* gene.^{6–11} Depending on the patients examined and the methods used for mutation analysis, germline mutations have been detected in 30–85% of FAP families. A correlation between site of mutation and clinical phenotype encompassing both colonic and extracolonic features has repeatedly been reported. Mutations at codon 1309 lead to the most severe intestinal phenotype characterised by a high number and early development of colorectal adenomas.^{2 12–14} A mild phenotype (attenuated FAP; AAFAP) with smaller numbers of adenomas (<100) and a later age of onset was found to be associated with mutations localised either in the 5' or 3' part of the gene^{15–20} or in the alternatively spliced fragment of exon 9.^{11 21–24} Some of the extracolonic manifestations of FAP, including congenital hypertrophy of the retinal pigment epithelium,^{25–27} desmoids, and osteomas have also been correlated with the site of *APC* mutation.^{27 28}

The discovery of the *APC* gene represents a breakthrough for carrier detection and surveillance in FAP families. While predictive testing among subjects at risk is now part of routine molecular genetic practice,^{9–11 29} the value of mutation analysis for therapeutic decisions is frequently overestimated among clinicians.

Based on 1256 patients with FAP who belonged to 680 families, we examined age of

Institute of Human Genetics, University of Bonn, Germany

W Friedl
M Sengteller
S Uhlhaas
J Fahnenstich
E Mangold
P Propping

Department of Medicine I, University of Bonn, Germany

R Caspari
C Lamberti
M Jungck

Department of Surgery, University of Heidelberg, Germany

M Kadmon
J Gebert

Department of Human Genetics, University of Ulm, Germany

M Wolf

Department of Surgery, University of Düsseldorf, Germany

G Möslin

Correspondence to:
Dr W Friedl, Institute of Human Genetics, University of Bonn, Wilhelmstrasse 31, D-53111 Bonn, Germany. friedlw@meh.uni-bonn.de

Accepted for publication
14 November 2000

Abbreviations used in this paper: FAP, familial adenomatous polyposis; *APC* gene, adenomatous polyposis coli gene; AAFAP, attenuated adenomatous polyposis coli; CRC, colorectal cancer; bp, base pairs.

onset, course of colorectal polyposis, and clinically relevant extracolonic manifestations according to the germline mutation. The aim of the study was to see if the known genotype-phenotype correlation allows therapeutic conclusions to be drawn for the individual patient.

Methods

PATIENTS

Blood samples from 680 unrelated patients with a clear diagnosis of FAP or suspected of having FAP were examined for *APC* germline mutations at the Institute of Human Genetics, Bonn. A total of 268 of the index patients presented with more than 100 colorectal adenomas; 101 patients had less than 100 adenomas. The number of adenomas was not known in 311 patients but most were reported to have "multiple adenomas characteristic of typical FAP" (table 1). Family histories revealed 357 index patients with at least one affected family member in previous generations. Fifty three patients seemed to have acquired a de novo mutation as both parents had negative colonoscopies at age >50 years or were still healthy at an advanced age. For 270 patients referred for genetic testing, no information on the parents was available or the parents had died at a young age from causes other than FAP (table 1). Clinical data of 1256 patients from the 680 families were obtained during genetic counselling or clinical management, or from medical records.

Table 1 *APC* germline mutations in 680 index patients grouped according to number of colorectal adenomas and family history

Subgroup according to No polyps and family history	No index patients	No <i>APC</i> germline mutations detected	Detection rate of germline mutations (%)
>100 adenomas	268	156	58.2
Familial	145	97	66.9
De novo*	31	26	83.9
No information	92	33	35.9
<100 adenomas	101	32	31.7
Familial	44	17	38.7
De novo	10	4	40.0
No information	47	11	23.4
No of adenomas unknown	311	139	44.7
Familial	168	99	58.9
De novo	12	10	83.3
No information	131	30	22.9
Total	680	327	48.1

*Both parents of patients classified as "de novo" had either negative colonoscopies at age >50 years or were still healthy at an advanced age.

Figure 1 Distribution of *APC* germline mutations in 327 of 680 FAP families (47 of the 53 patients had the 5 bp deletion at codon 1309).

We particularly documented whether the diagnosis of FAP was made after clinical bowel symptoms had developed (diarrhoea, rectal bleeding, abdominal pain) or through surveillance by endoscopy in subjects at risk. The study was approved by the local ethics committee.

MUTATION ANALYSIS

Genomic DNA was isolated from peripheral blood using standard protocols.³⁰ Total RNA was extracted from EDTA blood samples with Trizol (Life Technologies, Karlsruhe, Germany) according to the manufacturer's protocol. In the first 310 index patients, a search for mutations over the whole *APC* gene was performed with genomic DNA by non-radioactive single strand conformational polymorphism and heteroduplex analysis, as described previously,⁷ using the primers published by Groden and colleagues.³ In the remaining 370 index patients exon 15 was examined by protein truncation test in four fragments, essentially as described previously,³¹ with the in vitro transcription translation kit (Promega, Mannheim, Germany) in the presence of ³⁵S methionine (Amersham). When mRNA was available, cDNA was obtained by standard procedures, and exons 1–14 were examined by the protein truncation test in two fragments using the primers previously described.³² Polymerase chain reaction fragments showing variant bands by either method were sequenced using Sequenase version 2.0 (Amersham) in the presence of ³⁵S dATP or by semiautomated cycle sequencing with BigDye chain terminators with an ABI 377 sequencer (Applied Biosystems, Weiterstadt, Germany).

STATISTICAL COMPARISONS

Comparison of different clinical features in relation to the site of mutation were performed using the two tailed *t* test with unequal variance.

Results

MUTATION ANALYSIS

Pathogenic *APC* germline mutations were identified in 327 of the 680 index patients (48.1%). The mutation detection rate was 58.2% in patients diagnosed with >100 adenomas and 31.7% in patients with <100 adenomas (table 1). Remarkably, the mutation detection rate reached 59.7% in the 357 familial cases and 75.5% in the 53 patients with a de novo mutation.

Most of the mutations (322/327) were predicted to lead to truncated *APC* proteins, including 226 frameshift mutations due to small deletions/insertions, 87 nonsense mutations, and nine mutations in the highly conserved splice site sequences. In addition, four submicroscopic deletions uncovered through haplotype analysis in patients with normal behaviour and intelligence (Mandl and colleagues³³ and unpublished observations), and one large cytogenetically detectable deletion of about 10 Mb encompassing the entire *APC* gene in a patient with mild mental retardation³⁴ were observed. In accordance with previous reports, germline mutations were mainly distributed over the 5' half of the *APC* gene (fig 1). A total of 170 different mutations

Table 2 Novel APC germline mutations identified in 327 of 680 FAP families (mutations not reported in the APC mutation database)

Family	Exon	Codon	Mutation	Consequence
40			Deletion exon 11–15M	Genomic deletion
340			Deletion Exon 11–15M	Genomic deletion
367			Deletion Exon 11–3'utr	Genomic deletion
630			Deletion >10Mb (del5q22)	Genomic deletion
271	4	141	423–1g-c	Splice-acceptor site
406	4	141	423–5 a-g	Splice-acceptor site
595	4	150	450delAGAA	Frameshift
597	4	156	468delCTGGT	Frameshift
105, 389	4	170	509delATAG	Frameshift
228	4	171	512insATAG	Frameshift
571	5	181	541 TAC-TAA; Gln-Stop	Nonsense
33	9	433	1297 CAG-TAG; Glu-Stop	Nonsense
713	11	470	1409–5a-g	Splice-acceptor site
761	11	471	1412delG	Frameshift
44	12	518	1554 insC	Frameshift
82	13	561	1683delGA	Frameshift
336	13	567	1700delGAAGT	Frameshift
741	14	582	1744–2a-g	Splice-acceptor site
302, 536, 556	14	620	1859–1860insCT	Frameshift
327, 744	14	621	1863delTTAC	Frameshift
624	14	622	1866 TAC-TAG; Tyr-Stop	Nonsense
567	14	630	1890delC	Frameshift
483	14	653	1958+1g-t	Splice-donor site
491	14	653	1958+1g-a	Splice-donor site
550	15A	669	2005delTT	Frameshift
717	15A	747	2240 TCA-TGA; Ser-Stop	Nonsense
263	15B	781	2343delC	Frameshift
605	15B	799	2396delAT	Frameshift
649	15B	811	2432 TCA-TGA; Ser-Stop	Nonsense
295	15B	828	2483delC	Frameshift
562	15B	834	2502delC	Frameshift
746	15C	837	2510delC	Frameshift
173	15C	849	2546delATAGAAG	Frameshift
551	15C	857	2570delG	Frameshift
339	15C	900	2698insTG	Frameshift
559	15C	916	2748delA	Frameshift
493	15D	947	2840delG	Frameshift
139	15D	962	2884delG	Frameshift
507	15D	974	2921delG	Frameshift
191	15D	976	2926delA	Frameshift
463	15D	985	2953insT	Frameshift
350	15D	997	2991 TAT-TAG; Tyr-Stop	Nonsense
366	15D	1024	3071delC	Frameshift
675	15E	1044	3131 TCA-TAA; Ser-Stop	Nonsense
402	15E	1049	3147 TGG-TGA; Cys-Stop	Nonsense
101	15E	1050	3149delC	Frameshift
704	15E	1071	3211 CAA-TAA; Gln-Stop	Nonsense
255	15E	1072	3216delGT	Frameshift
514	15E	1107	3319insGGAG	Frameshift
361	15E	1132	3394delG	Frameshift
680	15F	1155	3464 del AAGAA	Frameshift
393, 728	15F	1156	3467delAAGA	Frameshift
408	15F	1166	3497insA	Frameshift
74	15F	1168	3502 GAA-TAA; Glu-Stop	Nonsense
421	15F	1169	3505delGAGAA	Frameshift
524	15F	1187	3559insA	Frameshift
76	15F	1201	3602 TCA-TGA; Ser-Stop	Nonsense
616	15F	1209	3625delGAAC	Frameshift
535	15F	1244	3730 CAA-TAA; Gln-Stop	Nonsense
325	15F	1256	3768insA	Frameshift
505	15F	1262	3786 TAT-TAA; Tyr-Stop	Nonsense
292, 480	15F	1267	3799insGATA	Frameshift
382	15F	1269	3805delA	Frameshift
221	15F	1269	3806insT	Frameshift
369	15F	1272	3816ins14bp	Frameshift
653	15G	1278	3833 TCA-TAA; Ser-Stop	Nonsense
697	15G	1298	3892–3903del12ins4	Frameshift
357	15G	1321	3963delC	Frameshift
601	15G	1341	4022delG	Frameshift
730, 747	15G	1341	4022ins22	Frameshift
202, 707	15G	1342	4025ins T	Frameshift
518	15G	1373	4118delT	Frameshift
68	15H	1432	4295delC	Frameshift
500	15H	1451	4351 GAA-TAA; Glu-Stop	Nonsense
650	15H	1462	4385delA	Frameshift
522	15I	1495	4483delA	Frameshift
608	15I	1498	4492delG	Frameshift
655	15I	1517	4549 CAG-TAG; Gln-Stop	Nonsense
426	15I	1531	4592insA	Frameshift
400	15I	1541	4621 CAG-TAG; Gln-Stop	Nonsense
97	15I	1548	4643delA	Frameshift
84	15I	1556	4666insA	Frameshift
401	15I	1564	4693 TTA-TAA; Leu-Stop	Nonsense
591	15L	1823	5471delA	Frameshift
546	15N	1958	5873delA	Frameshift
701	15N	1986	5957delT	Frameshift
414	15T	2557	7671delCCTTCCTC	Frameshift

were identified, including 86 novel mutations (table 2) not reported in the APC mutation data base (<http://www.umd.necker.fr>).

Mutational hotspots published in other FAP patient populations^{6–9,10} were also observed in our patients. Deletion of 5 base pairs (bp) at codon 1309 was present in 47 of the 680 index patients (6.9%). All except one patient showed typical or very early onset FAP. The one patient who developed symptoms at age 53 had a de novo mutation. The unusually mild phenotype in this patient (100–200 adenomas without dysplasia at age 53) might eventually be due to a somatic mosaic. One of his sons who inherited the 5 bp deletion at codon 1309 was still asymptomatic at age 17; at colonoscopy performed following predictive genetic testing innumerable small polyps were detected. Another six patients had a 4 bp deletion or a nonsense mutation at codon 1309. Deletion of 5 bp at codon 1061 was detected in 33 index patients (4.9%), all of whom suffered from typical FAP. At least 17/47 mutations at codon 1309 and 5/33 mutations at codon 1061 had occurred de novo in the index patients, as demonstrated by exclusion of the mutations in both parents (data not shown).

PARAMETERS FOR SEVERITY OF COLORECTAL POLYPOSIS

Age at appearance of first colonic adenomas, and number of polyps and their progression during a defined interval of several years would be the most accurate parameter for studying the natural course of the disease. However, so far such data are available only for a small number of patients at risk who underwent regular colonoscopies starting at an early age. Age at clinical diagnosis of FAP in asymptomatic subjects at risk is largely dependent on age at first endoscopy and whether surveillance has been performed regularly. Therefore, we considered that age at diagnosis in this patient group was not suitable for comparison.

Further indicators of the severity of the natural course of bowel disease ascertained in a retrospective study are age at diagnosis of FAP in patients who have developed bowel symptoms characteristic of FAP (rectal bleeding, diarrhoea, etc) prior to their first endoscopy, and age at which CRC occurs in untreated patients. Therefore, we determined how the diagnosis of FAP or CRC was made.

Age at clinical diagnosis of FAP was known for 404 patients who had developed bowel symptoms prior to diagnosis and for 292 patients who were diagnosed on the basis of a surveillance programme offered to subjects at risk (table 3). As expected, mean age at diagnosis of FAP was lower in the surveillance group (25.4 years) compared with the group of patients who were diagnosed after they had developed symptoms (32.9 years).

Overall, CRC was diagnosed in 193 of 1256 patients (15.4%), with a mean age of 40.7 years (table 3). A total of 126 of 410 patients diagnosed because of bowel symptoms (30.7%) developed CRC; 107 (26.2%) were found to have CRC at the time of diagnosis of FAP. In the group of 303 patients diagnosed

Table 3 Age at diagnosis in familial adenomatous polyposis (FAP) patients grouped according to the method of diagnosis

Diagnosis based on	No patients	Known age at diagnosis	Age at diagnosis of FAP (y)	No patients with CRC (%)	Age at diagnosis of CRC (y)
Bowel symptoms	410	404	32.9 (13.9) [4–78]	126 (30.7)	40.1 (12.4) [19–78]
Surveillance	303	292	25.4 (12.2) [4–64]	18 (5.9)	36.9 (9.7) [21–54]
“Chance”	13	13	40.3 (14.9) [23–63]	4 (30.8)	40.5 (6.9) [32–49]
Unknown	530	161	37.5 (14.8) [8–78]	45 (8.5)	44.0 (13.6) [22–76]
Total	1256	870		193 (15.4)	40.7 (12.5) [19–78]

Values are number or mean (SD) [range].

while on surveillance, only 18 (5.9%) developed CRC; 11 (3.6%) presented with CRC at the time of diagnosis.

Similar data regarding age at diagnosis of FAP or CRC, respectively, were observed in the group of Danish FAP patients.¹

As not all subjects at risk diagnosed during surveillance had undergone regular colonoscopies from a young age, clinical data from this group were not included in the genotype-phenotype analysis. Rather, age at diagnosis of FAP or CRC, respectively, was evaluated only in relation to the germline mutation in the group of 404 untreated patients diagnosed after spontaneous bowel symptoms had developed.

Table 4 Relationship between mutation site and age at diagnosis achieved after bowel symptoms had developed in 230 patients with known mutations and in 174 patients with unknown mutations

Group	APC mutation	Predicted phenotype	No patients	Age at diagnosis (y) (mean (SD))
1	Codon 139–156 Codon 332 (exon 9) Codon 1596–2557	AAPC	11	52.2 (16.5)
2	Codon 170–1578 (except 1309; 332)	Typical FAP	169	30.4 (10.0)
3	Codon 1309	Severe FAP	45	19.8 (11.5)
4	Large deletions	?	5	27.8 (5.9)
5	No mutation identified	?	174	37.7 (14.4)
6	All patients		404	32.9 (13.9)

Statistical comparisons (two tailed *t* test for unequal samples): 1 v 2, $p=0.0028$; 1 v 3, $p<0.0001$; 1 v 5, $p=0.0159$; 2 v 5, $p<0.0001$; 3 v 5, $p<0.0001$; 2 v 3, $p<0.0001$.

FAP, familial adenomatous polyposis; AAPC, attenuated adenomatous polyposis coli.

Figure 2 Age at diagnosis of familial adenomatous polyposis (FAP) due to bowel symptoms in 230 patients with identified germline mutations, in those in whom colorectal cancer (CRC) was present at diagnosis of FAP and in those without CRC. Mutations outside the vertical lines at codons 168 and 1580, and at codon 332 (in the alternatively spliced fragment of exon 9), respectively, are considered to be associated with attenuated FAP. Patients with large genomic deletions are depicted as “null alleles” at codon 0.

GENOTYPE-PHENOTYPE CORRELATION

According to the literature, attenuated FAP is associated with mutations 5' to codon 168, 3' to codon 1580, or in the alternatively spliced part of exon 9, and a very severe clinical phenotype is present in patients with mutations at codon 1309, while typical FAP is observed in patients with mutations at other sites. The germline mutation was uncovered in 230 of 404 patients who were diagnosed after onset of bowel symptoms. When grouping patients according to the mutation intervals outlined above, a consistent correlation between the APC mutation site and average age at diagnosis of FAP was observed (table 4). Patients with a mutation at codon 1309 developed bowel symptoms more than 10 years earlier (19.8 years) compared with patients with other mutations: 52.2 years in patients with mutations at sites characteristic of attenuated FAP and 30.4 years in patients with mutations at other sites ($p<0.0001$ for all comparisons). This observation independently supports earlier findings.²

Despite this clear genotype-phenotype relationship observed when mean values were compared, there was a wide variation in age at onset of intestinal symptoms within each of the subgroups, even among patients with identical mutations. Figure 2 presents age at diagnosis of FAP due to bowel symptoms in 230 individual patients from 205 families in relation to the site of their germline mutation. Only patients with mutations at codon 1309 (or close to this codon) were diagnosed before the age of 10 years. However, an appreciable number of patients with this mutation developed symptoms only at age 30–40 or even at age 53.

Large variations within patients with the same mutation were also observed when age at diagnosis of CRC in untreated patients was considered (figs 2, 3). The germline mutation was known in 97 of the 193 patients who developed CRC; in these 97 patients CRC was diagnosed at a mean age of 36.9 (0.9) years. CRC was diagnosed in 10 patients with the mutation at codon 1309 at a mean age of 28.8 years, with a large range between 19 and 41 years.

CLINICALLY RELEVANT EXTRACOLONIC MANIFESTATIONS

Adenomas of the duodenum and desmoid tumours represent extracolonic features with important clinical implications. Adenomas of the duodenum were reported in 134 patients from 125 families. In 86 patients from 77 families the germline mutation was known, being

Figure 3 Age at diagnosis of colorectal cancer (CRC) in 97 patients with a known APC germline mutation. This group includes patients who had developed CRC at the time of diagnosis of familial adenomatous polyposis (FAP) (see fig 2) and patients who developed cancer one to several years after diagnosis of FAP.

localised between codons 156 and 1563, with a distribution that resembled the overall distribution of germline mutations in the index patients (fig 4). Thus no correlation between the presence of adenomas in the duodenum and site of mutations was evident.

Figure 4 Presence of duodenal adenomas in 86 patients with different germline mutations.

Figure 5 Presence or absence of clinically manifest desmoid disease in 269 patients with identified germline mutations. The insert shows patients with mutations within codons 1445–1578.

Information on the presence or absence of clinically manifest desmoid disease was obtained from 269 patients with identified mutations. Sixty five of these patients presented with desmoids (overall 24%). Although in patients with desmoids the APC mutations were spread over large parts of the gene, an uneven distribution was observed (fig 5). Desmoids were found in only 20% of patients with mutations 5' to codon 1444 (46/230) but occurred in 49% (19/39) of patients with mutations 3' to this codon and in 61% (17/28) of patients with mutations within codons 1445–1580 (fig 4, insert). Only two of 11 patients with mutations 3' to codon 1580 developed desmoids.

Discussion

Examination of APC germline mutations in FAP families is being used as an efficient tool for predictive testing of subjects at risk. If the germline mutation causing the disease is known in a given family, it is possible to clearly distinguish between carriers who need to undergo surveillance by regular endoscopies and non-carriers who can be excluded from a surveillance programme.

Mutation analysis in large samples of FAP patients has revealed a consistent correlation between the site of mutation in the APC gene and severity of intestinal polyposis or presence of clinically relevant extracolonic features.^{2 12 15 18 19 23 27} We too found this correlation in the present study. This relationship may be explained in part by recent studies demonstrating that the site of the germline mutation modulates the spectrum of somatic APC mutations which lead to adenoma formation. Tumours from patients with attenuated FAP and a germline mutation at the 5' end of the gene frequently maintain the wild-type allele³⁵ whereas adenomas from patients with germline mutations close to codon 1300 display loss of the wild-type allele more frequently compared with patients with mutations at other sites, thus providing a greater selective advantage to these cells.³⁶ These findings may explain clinical observations in patients with the 5 bp deletion at codon 1309. Patients with this mutation tend to develop adenomas more frequently and at an earlier age than patients with other mutations.

An important question is whether the known genotype-phenotype relationship in FAP can be helpful for individual therapeutic decisions in either presymptomatic or symptomatic mutation carriers. Initial recommendations on application of molecular genetic tests as a guide to surgical management of FAP patients³⁷ were based on the observation of a higher rate of rectal cancer in patients with mutations 3' to codon 1250 compared with patients with mutations 5' to this codon. The authors recommended a restorative proctocolectomy instead of a colectomy with ileorectal anastomosis for patients with mutations 3' of codon 1250. However, this recommendation was later revoked^{38 39} as in the meantime several families with mild polyposis were found to have mutations in the 3' half of the gene.^{17 40 41}

Our results demonstrate a large variation with respect to both age at onset of intestinal symptoms and development of CRC even in patients with the same mutation (fig 2). In accordance with these data, variable phenotypes were reported within large FAP families.^{16 20 42 43} The observed variation may be caused by modifier genes or other endogenous or exogenous factors, or even by chance, as the "second hit"⁴⁴ inactivating APC and inducing tumour growth occurs as a stochastic event. Thus the site of the APC mutation, although statistically correlated with the natural course of the disease, cannot predict its course in the individual patient.

Regarding clinically relevant extracolonic features, we found no correlation between the site of mutation and presence of duodenal adenomas. These results are in line with a recent study which reports a cumulative lifetime incidence for duodenal polyps of 97%.⁴⁵ A higher incidence of desmoid tumours in patients with mutations located 3' to codon 1444 compared with patients with mutations 5' to this codon has consistently been reported by us and others,^{27 28} and was again confirmed in this study. However, not all patients with mutations 3' to codon 1444 developed clinical desmoid disease although a subclinical manifestation cannot be excluded. Desmoids may develop particularly after surgical intervention. As at least 60% of patients with mutations within codons 1445–1580 develop desmoids, it seems advisable to postpone elective colectomy in patients with such mutations until disease progression in the colon is substantial. This decision requires the expertise of highly experienced clinicians.

In conclusion, identification of germline mutations in FAP patients is important for predictive testing in subjects at risk. Our analysis in a large number of FAP families showed that mutation analysis is of limited value for predicting the clinical course of the disease and for surgical decisions in individual patients, given the large phenotypic variation in patients with identical APC mutations. Therefore, decisions on clinical management have to be based on the degree of colonic polyposis. Nevertheless, other factors, including the presence of desmoids in the patient or in the patient's family, and their higher incidence in patients with mutations beyond codon 1444, also have to be taken into consideration. It is imperative that FAP families be referred for genetic counselling, genetic testing, early diagnosis, and clinical management to centres that are aware of the complexity of both surgical intervention and possible implications of molecular findings for individual patients.

The authors are grateful to the patients who participated in the study and to the many colleagues who contributed clinical data. The help of Vera Breisig for technical assistance is also kindly acknowledged. The study was supported by the Deutsche Krebshilfe within the national collaborative study on familial colon cancer.

- 1 Bülow S. Clinical features in familial polyposis coli. Results of the Danish Polyposis Register. *Dis Colon Rectum* 1986;29:102–7.
- 2 Caspari R, Friedl W, Mandl M, et al. Familial adenomatous polyposis: mutation at codon 1309 and early onset of colon cancer. *Lancet* 1994;343:629–32.

- 3 Groden J, Thliveris A, Samowitz W, et al. Identification and characterization of the familial adenomatous polyposis coli gene. *Cell* 1991;66:589–600.
- 4 Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. *Science* 1991;253:661–5.
- 5 Morin PJ. Beta-catenin signaling and cancer. *Bioessays* 1999;21:1021–30.
- 6 Miyoshi Y, Ando H, Nagase H, et al. Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. *Proc Natl Acad Sci USA* 1992;89:4452–6.
- 7 Mandl M, Paffenholz R, Friedl W, et al. Frequency of common and novel inactivating APC mutations in 202 families with familial adenomatous polyposis. *Hum Mol Genet* 1994;3:181–4.
- 8 Paffenholz R, Mandl M, Caspari R, et al. Eleven novel germline mutations in the adenomatous polyposis coli (APC) gene. *Hum Mol Genet* 1994;3:1703–4.
- 9 van der Luijt RB, Khan PM, Vasen HF, et al. Molecular analysis of the APC gene in 105 Dutch kindreds with familial adenomatous polyposis: 67 germline mutations identified by DGGE, PTT, and southern analysis. *Hum Mutat* 1997;9:7–16.
- 10 Wallis YL, Morton DG, McKeown CM, et al. Molecular analysis of the APC gene in 205 families: extended genotype-phenotype correlations in FAP and evidence for the role of APC amino acid changes in colorectal cancer predisposition. *J Med Genet* 1999;36:14–20.
- 11 Gebert JF, Dupon C, Kadmon M, et al. Combined molecular and clinical approaches for the identification of families with familial adenomatous polyposis coli. *Ann Surg* 1999;229:350–61.
- 12 Nagase H, Miyoshi Y, Horii A, et al. Correlation between the location of germ-line mutations in the APC gene and the number of colorectal polyps in familial adenomatous polyposis patients. *Cancer Res* 1992;52:4055–7.
- 13 Nugent KP, Phillips RK, Hodgson SV, et al. Phenotypic expression in familial adenomatous polyposis: partial prediction by mutation analysis. *Gut* 1994;35:1622–3.
- 14 Paul P, Letteboer T, Gelbert L, et al. Identical APC exon 15 mutations result in a variable phenotype in familial adenomatous polyposis. *Hum Mol Genet* 1993;2:925–31.
- 15 Spirio L, Olschwang S, Groden J, et al. Alleles of the APC gene: an attenuated form of familial polyposis. *Cell* 1993;75:951–7.
- 16 Scott RJ, van der Luijt R, Spycher M, et al. Novel germline APC gene mutation in a large familial adenomatous polyposis kindred displaying variable phenotypes. *Gut* 1995;36:731–6.
- 17 Friedl W, Meuschel S, Caspari R, et al. Attenuated familial adenomatous polyposis due to a mutation in the 3' part of the APC gene. A clue for understanding the function of the APC protein. *Hum Genet* 1996;97:579–84.
- 18 van der Luijt RB, Meera Khan P, Vasen HF, et al. Germline mutations in the 3' part of APC exon 15 do not result in truncated proteins and are associated with attenuated adenomatous polyposis coli. *Hum Genet* 1996;98:727–34.
- 19 Giardiello FM, Brensinger JD, Luce MC, et al. Phenotypic expression of disease in families that have mutations in the 5' region of the adenomatous polyposis coli gene. *Ann Intern Med* 1997;126:514–19.
- 20 Brensinger JD, Laken SJ, Luce MC, et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutations in the APC gene. *Gut* 1998;43:548–52.
- 21 Curia MC, Esposito DL, Aceto G, et al. Transcript dosage effect in familial adenomatous polyposis: model offered by two kindreds with exon 9 APC gene mutations. *Hum Mutat* 1998;11:197–201.
- 22 Bunyan DJ, Shea Simonds J, Reck AC, et al. Genotype-phenotype correlations of new causative APC gene mutations in patients with familial adenomatous polyposis. *J Med Genet* 1995;32:728–31.
- 23 Soravia C, Berk T, Madlensky L, et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. *Am J Hum Genet* 1998;62:1290–301.
- 24 van der Luijt RB, Vasen HF, Tops CM, et al. APC mutation in the alternatively spliced region of exon 9 associated with late onset familial adenomatous polyposis. *Hum Genet* 1995;96:705–10.
- 25 Olschwang S, Turet A, Laurent Puig P, et al. Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. *Cell* 1993;75:959–68.
- 26 Wallis YL, Macdonald F, Hulten M, et al. Genotype-phenotype correlation between position of constitutional APC gene mutation and CHRPE expression in familial adenomatous polyposis. *Hum Genet* 1994;94:543–8.
- 27 Caspari R, Olschwang S, Friedl W, et al. Familial adenomatous polyposis: desmoid tumors and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. *Hum Mol Genet* 1995;4:337–40.
- 28 Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. *Br J Surg* 1996;83:1494–504.
- 29 Giardiello FM, Brensinger JD, Petersen GM, et al. The use and interpretation of commercial APC gene testing for familial adenomatous polyposis. *N Engl J Med* 1997;336:823–7.
- 30 Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. *Nucleic Acids Res* 1988;16:1215.
- 31 van der Luijt R, Khan PM, Vasen H, et al. Rapid detection of translation-terminating mutations at the adenomatous polyposis coli (APC) gene by direct protein truncation test. *Genomics* 1994;20:1–4.

- 32 Bala S, Kraus C, Wijnen J, *et al.* Multiple products in the protein truncation test due to alternative splicing in the adenomatous polyposis coli (APC) gene. *Hum Genet* 1996; **98**:528–33.
- 33 Mandl M, Caspari R, Jauch A, *et al.* Familial adenomatous polyposis: a submicroscopic deletion at the APC locus in a family with mentally normal patients. *Hum Genet* 1996; **97**: 204–8.
- 34 Rädle J, Friedl W, Engels H, *et al.* A de novo deletion of chromosome 5q causing familial adenomatous polyposis, dysmorphic features, and mild mental retardation. *Am J Gastroenterol* 2001 (in press).
- 35 Spirio LN, Samowitz W, Robertson M, *et al.* Alleles of APC modulate the frequency and classes of mutations that lead to colon polyps. *Nat Genet* 1998; **20**:385–8.
- 36 Lamlum H, Ilyas M, Rowan A, *et al.* The type of somatic mutation at APC in familial adenomatous polyposis is determined by the site of the germline mutation: a new facet to Knudson's 'two-hit' hypothesis. *Nat Med* 1999; **5**: 1071–5.
- 37 Vasen HF, van der Luijt RB, Slors JF, *et al.* Molecular genetic tests as a guide to surgical management of familial adenomatous polyposis. *Lancet* 1996; **348**:433–5.
- 38 Vasen HF, van der Luijt RB, Tops C, *et al.* Molecular genetic tests in surgical management of familial adenomatous polyposis. *Lancet* 1998; **351**:1131–2.
- 39 Evans DG, Evans D, Hill J, *et al.* Molecular genetic tests in surgical management of familial adenomatous polyposis. *Lancet* 1997; **350**:1777.
- 40 Scott RJ, Froggatt NJ, Trembath RC, *et al.* Familial infiltrative fibromatosis (desmoid tumours) (MIM135290) caused by a recurrent 3' APC gene mutation. *Hum Mol Genet* 1996; **5**:1921–4.
- 41 Eccles DM, van der Luijt R, Breukel C, *et al.* Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. *Am J Hum Genet* 1996; **59**:1193–201.
- 42 Giardiello FM, Krush AJ, Petersen GM, *et al.* Phenotypic variability of familial adenomatous polyposis in 11 unrelated families with identical APC gene mutation. *Gastroenterology* 1994; **106**:1542–7.
- 43 Rozen P, Samuel Z, Shomrat R, *et al.* Notable intrafamilial phenotypic variability in a kindred with familial adenomatous polyposis and an APC mutation in exon 9. *Gut* 1999; **45**:829–33.
- 44 Knudson AG. Mutation and cancer. Statistical study of retinoblastoma. *Proc Natl Acad Sci USA* 1971; **68**:820–3.
- 45 Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. *Endoscopy* 1999; **31**:412–16.